Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dijia Xin
Institutions:
Second Affiliated Hospital of Zhejiang University,
Zhejiang University
Observed institutions:
Second Affiliated Hospital of Zhejiang University,
Zhejiang University
ORCID:
0009-0005-6901-2514
Observed ORCID:
0009-0005-6901-2514
OpenAlex ID:
A5006708838
Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials
2022
·
Yang Xu
, Ping Li
, et al.
·
癌症:英文版
·
49
CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2024
·
Yang Xu
, Xuzhao Zhang
, et al.
·
Cancer Immunology Research
·
14
Glycosyltransferase-related long non-coding RNA signature predicts the prognosis of colon adenocarcinoma
2022
·
Jiawei Zhang
, Yinan Wu
, et al.
·
Frontiers in Oncology
·
12
PDF
Increased Expression of SRSF1 Predicts Poor Prognosis in Multiple Myeloma
2023
·
Jiawei Zhang
, Zanzan Wang
, et al.
·
Journal of Oncology
·
10
PDF
Plasma proteins and onset of atherosclerosis: integrating human plasma proteogenomics, transcriptomics and in vivo evidence
2025
·
Kuangyang Chen
, Yifeng Pan
, et al.
·
Journal of Translational Medicine
·
8
PDF
CD27-Armored BCMA-CAR T Cell (CBG-002) Therapy for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2023
·
Yang Xu
, Xuzhao Zhang
, et al.
·
Blood
·
6
Genome-wide CRISPR screening identifies critical role of phosphatase and tensin homologous (PTEN) in sensitivity of acute myeloid leukemia to chemotherapy
2024
·
Liming Lin
, Jingjing Tao
, et al.
·
Journal of Zhejiang University SCIENCE B
·
1
PDF
TRIM28 Regulates DHCR7-Mediated Cholesterol Biosynthesis to Promote Survival in B Cell Lymphoma
2023
·
Jiawei Zhang
, Dijia Xin
, et al.
·
Blood
·
1
Figure S2 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2026
·
Yang Xu
, Xuzhao Zhang
, et al.
Figure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2026
·
Yang Xu
, Xuzhao Zhang
, et al.
Figure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2026
·
Yang Xu
, Xuzhao Zhang
, et al.
Figure S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2026
·
Yang Xu
, Xuzhao Zhang
, et al.
Protective effects of a herbal combination ( Dimocarpus longan and Orthosiphon stamineus ) on metabolic-associated fatty liver disease via the ERα-PI3K-AKT pathway
2026
·
Han Yan
, Song Zhu
, et al.
·
Food & Function
Table S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025
·
Yang Xu
, Xuzhao Zhang
, et al.
Figure S4 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025
·
Yang Xu
, Xuzhao Zhang
, et al.
Figure S1 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025
·
Yang Xu
, Xuzhao Zhang
, et al.
Figure S2 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025
·
Yang Xu
, Xuzhao Zhang
, et al.
Figure S3 from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025
·
Yang Xu
, Xuzhao Zhang
, et al.
Data from CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial
2025
·
Yang Xu
, Xuzhao Zhang
, et al.
Case Report: Radiation necrosis mimicking tumor progression in a patient with extranodal natural killer/T-cell lymphoma
2023
·
Boxiao Chen
, Yili Fan
, et al.
·
Frontiers in Radiology
PDF
Cover Image, Volume 42, Issue 6
2022
·
Yang Xu
, Ping Li
, et al.
·
癌症:英文版
Show more works
View as search
Works count:
21
Citation count:
101
H-index:
6
I10-index:
4
Year
Topic
Type